Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PGK1 | P00558 | 1/20 | 0.43 |
| ▸ | PGK2 | P07205 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30722883 | 0.83 | PGK1 (0.37) | PGK1PGK2 | |
| SCHEMBL27042415 | 0.83 | CYP3A4 (0.44) | CYP3A4 | |
| SCHEMBL10988240 | 0.82 | ESR1 (0.49) | CYP3A4 | |
| SCHEMBL10985358 | 0.79 | CYP3A4 (0.40) | CYP3A4 | |
| SCHEMBL2032073 | 0.78 | CYP3A4 (0.45) | CYP3A4 | |
| SCHEMBL5550099 | 0.77 | CETP (0.47) | CYP3A4 | |
| SCHEMBL19602994 | 0.77 | ENPP2 (0.45) | — | |
| SCHEMBL22187687 | 0.77 | ENPP2 (0.45) | — | |
| SCHEMBL914599 | 0.75 | HMGCR (0.50) | CYP3A4 | |
| SCHEMBL6769527 | 0.75 | CYP3A4 (0.42) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | JAL THERAPEUTICS LLC (US) | 2026-01-15 | — | — | US | claimed |
| WO-2024020507-A2 | ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF | JAL THERAPEUTICS, LLC (US) | 2024-01-25 | — | — | WO | claimed |
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | JAL THERAPEUTICS LLC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2024020507-A2 | ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF | JAL THERAPEUTICS, LLC (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020507-A2 | ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF | JAL THERAPEUTICS, LLC (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | ACHE, BCHE, MUSK | CYP3A4 1005/4885PGK1 2600/4885PGK2 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.